Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

xentuzumab (BI-836845)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim, Novartis

Drug class:

IGF-2 inhibitor, IGF1 inhibitor

‹

›

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	everolimus + BI-836845 Sensitive: C3 – Early Trials everolimus + BI-836845 Sensitive : C3	everolimus + BI-836845 Sensitive: C3 – Early Trials everolimus + BI-836845 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib + BI-836845 Sensitive: C3 – Early Trials abemaciclib + BI-836845 Sensitive : C3	abemaciclib + BI-836845 Sensitive: C3 – Early Trials abemaciclib + BI-836845 Sensitive : C3
IGF1 overexpression	Prostate Cancer	IGF1 overexpression	Prostate Cancer	enzalutamide + BI-836845 Sensitive: C3 – Early Trials enzalutamide + BI-836845 Sensitive : C3	enzalutamide + BI-836845 Sensitive: C3 – Early Trials enzalutamide + BI-836845 Sensitive : C3
PTEN overexpression	Prostate Cancer	PTEN overexpression	Prostate Cancer	enzalutamide + BI-836845 Sensitive: C3 – Early Trials enzalutamide + BI-836845 Sensitive : C3	enzalutamide + BI-836845 Sensitive: C3 – Early Trials enzalutamide + BI-836845 Sensitive : C3
IGF2 overexpression	Hepatocellular Cancer	IGF2 overexpression	Hepatocellular Cancer	BI-836845 Sensitive: D – Preclinical BI-836845 Sensitive : D	BI-836845 Sensitive: D – Preclinical BI-836845 Sensitive : D